Carmen Moreno

Carmen Moreno

Auto-generated profile, based on publicly available information

Carmen Moreno

Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Maranon, IiSGM, CIBERSAM, ISCIII, School of Medicine, Universidad Complutense, Madrid, Spain

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in The Lancet Psychiatry
Verified
Journal Article
Closed access
CMCarmen Moreno
Carmen Moreno
TWTil Wykes
Til Wykes
SGSilvana Galderisi
Silvana Galderisi
MNMerete Nordentoft
Merete Nordentoft
NCNicolas Crossley
Nicolas Crossley
CACelso Arango
Celso Arango

1 September 2007 in Archives of General Psychiatry
Verified
Journal Article
Open access
PDF file
CMCarmen Moreno
Carmen Moreno
GLGonzalo Laje
Gonzalo Laje
CBCarlos Blanco
Carlos Blanco
HJHuiping Jiang
Huiping Jiang
ASAndrew B. Schmidt
Andrew B. Schmidt
MOMark Olfson
Mark Olfson
Accumulating evidence suggests that there has been a recent increase in the clinical diagnosis of bipolar disorder among young people.1,2 Between 1995 and 2000, the proportion of youth in a large database of privately insured patients who received outpatient treatment for bipolar disorder increased by 67%2 while the proportion who received inpatient treatment for bipolar disorder increased by 74%.1 Recent reports3-5 further indicate that children and adolescents commonly receive pharmacological treatments for bipolar disorder. However, 1 recent study6 suggests that children and adolescents diagnosed with bipolar disorder are somewhat less likely than their adult counterparts to be prescribed mood stabilizers. The extent to which there has been a recent national increase in the outpatient diagnosis of childhood bipolar disorder and the pattern of its pharmacological treatment remain unknown.

1 October 2020 in Journal of Affective Disorders
Verified
Journal Article
Closed access
GPGonzalo Salazar de Pablo
Gonzalo Salazar de Pablo
JVJulio Vaquerizo-Serrano
Julio Vaquerizo-Serrano
ACAna Catalan
Ana Catalan
CACelso Arango
Celso Arango
CMCarmen Moreno
Carmen Moreno
PFPaolo Fusar-Poli
Paolo Fusar-Poli

1 June 2006 in Archives of General Psychiatry
Verified
Journal Article
Open access
PDF file
MOMark Olfson
Mark Olfson
CBCarlos Blanco
Carlos Blanco
LLLinxu Liu
Linxu Liu
CMCarmen Moreno
Carmen Moreno
GLGonzalo Laje
Gonzalo Laje
Studies1-3 of privately and publicly insured populations indicate recent growth in the treatment of young people with antipsychotic drugs. In a large privately insured prescription database, for example, treatment of youth younger than 18 years with antipsychotic medications increased from 0.32% in 1997 to 0.50% in 2000.1 In Texas, the number of child and adolescent Medicaid enrollees prescribed second-generation antipsychotic medications increased 494% between 1996 and 2000, and the number prescribed first-generation antipsychotic medications increased 160% during that period.2 Similar increases in youth antipsychotic treatment have been reported among the Tennessee Medicaid population.3

1 February 2023 in BMJ Mental Health
Verified
Journal Article
Open access
PDF file
KSKatharine A Smith
Katharine A Smith
CBCharlotte Blease
Charlotte Blease
MFMaria Faurholt-Jepsen
Maria Faurholt-Jepsen
JFJoseph Firth
Joseph Firth
TDTom Van Daele
Tom Van Daele
ACAndrea Cipriani
Andrea Cipriani
Digital innovations in mental health offer great potential, but present unique challenges. Using a consensus development panel approach, an expert, international, cross-disciplinary panel met to provide a framework to conceptualise digital mental health innovations, research into mechanisms and effectiveness and approaches for clinical implementation. Key questions and outputs from the group were agreed by consensus, and are presented and discussed in the text and supported by case examples in an accompanying appendix. A number of key themes emerged. (1) Digital approaches may work best across traditional diagnostic systems: we do not have effective ontologies of mental illness and transdiagnostic/symptom-based approaches may be more fruitful. (2) Approaches in clinical implementation of digital tools/interventions need to be creative and require organisational change: not only do clinicians and patients need training and education to be more confident and skilled in using digital technologies to support shared care decision-making, but traditional roles need to be extended, with clinicians working alongside digital navigators and non-clinicians who are delivering protocolised treatments. (3) Designing appropriate studies to measure the effectiveness of implementation is also key: including digital data raises unique ethical issues, and measurement of potential harms is only just beginning. (4) Accessibility and codesign are needed to ensure innovations are long lasting. (5) Standardised guidelines for reporting would ensure effective synthesis of the evidence to inform clinical implementation. COVID-19 and the transition to virtual consultations have shown us the potential for digital innovations to improve access and quality of care in mental health: now is the ideal time to act.

1 August 2011 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
DFDavid Fraguas
David Fraguas
CCChristoph U. Correll
Christoph U. Correll
JMJessica Merchán-Naranjo
Jessica Merchán-Naranjo
MRMarta Rapado-Castro
Marta Rapado-Castro
MPMara Parellada
Mara Parellada
CACelso Arango
Celso Arango